Drug Trial Radar · NCT06145373
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Mar 1, 2024
Primary completion
May 28, 2028
Study completion Jan 30, 2030
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an exploratory, single group, Phase 4, study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis. This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study will be conducted in male participants with severe hemophilia A, with or without inhibitors, aged ≥12 years, who were previously receiving emicizumab prophylaxis. Study details include: * The study duration will be up to approximately 28 months: * There will be an approximately 2-month screening period. * There will be an approximately 2-month period before fitusiran treatment starts (pre-fitusiran treatment period) * The fitusiran treatment duration will be up to 18-months (fitusiran treatment period) * The antithrombin (AT) follow-up (FU) period will be approximately 6 months after the last dose of fitusiran (during which the AT activity level will be monitored at approximately monthly intervals following the final fitusiran dose until AT activity levels return to at least 60%). * The study site visits are scheduled at monthly/ every 2 months intervals of 28 days (4 weeks) / 56 days (8 weeks), respectively, during the fitusiran treatment period.
Conditions
- Hemophilia A
Interventions
Fitusiran (SAR439774)Drug
Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous (SC) injection
Clotting factor concentrates (CFC) or bypassing agents (BPA)Biological
Pharmaceutical form: Solution for injection-Route of administration: Intravenous (IV) injection
Antithrombin concentrate (ATIIIC)Biological
Pharmaceutical form:Solution for injection-Route of administration:Intravenous (IV) injection
EmicizumabBiological
Pharmaceutical form:Solution for injection-Route of administration:SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse events (AEs) during the fitusiran treatmentTime frame: From Day 1 up to Month 4
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles- Site Number : 8400005
Los Angeles, California · Recruiting
Southern Specialty Research- Site Number : 8400011
Flowood, Mississippi · Recruiting
Investigational Site Number : 1580001
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.